
Loading, please wait...

Loading, please wait...

The FSSAI recently issued a critical advisory regarding the inclusion of Withania somnifera in dietary products. This directive clarifies that manufacturers must prioritize Ashwagandha root extracts and roots in health supplements and nutraceuticals. Furthermore, the FSSAI emphasizes compliance with the 2016 regulations to ensure consumer safety across India.
Only certain plant parts are safe for human consumption according to Schedule IV of the 2016 regulations. Specifically, the advisory permits only the roots and Ashwagandha root extracts for use in nutraceuticals and functional foods. However, these ingredients must still adhere to prescribed limits and quality standards. Consequently, manufacturers must verify their raw materials to meet these strict legal requirements.
Recent reports indicated that some manufacturers were using Ashwagandha leaves or leaf extracts in their products. Consequently, the FSSAI explicitly stated that the use of leaves in any form is currently not permitted. This decision aligns with previous directives from the Ministry of Ayush, which also limited product formulations to roots. Therefore, any product containing leaf-based ingredients is now considered non-compliant under the Food Safety and Standards Act of 2006.
Food Business Operators (FBOs) must ensure their products align with these updated guidelines immediately. Furthermore, licensing authorities and food safety officers are now under instructions to maintain strict vigilance. Any observed deviation from these standards will lead to legal action. As a result, businesses should review their formulations to avoid penalties and ensure public health safety.
Q1: Which parts of Ashwagandha are allowed in food products?
Only the roots and Ashwagandha root extracts are permitted under current FSSAI regulations for health supplements and nutraceuticals.
Q2: Why are Ashwagandha leaves prohibited?
The FSSAI and Ministry of Ayush have not authorized the use of leaves in food products, focusing on the historical and safety data associated with the roots.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


FSSAI issues an advisory restricting Ashwagandha use in food products to roots and extracts only, prohibiting the use of leaves due to safety regulations....
3 months ago

Discover clinical pitfalls in diagnosing SGLT2 inhibitor ketoacidosis in the ICU. Learn how cardiac surgery and GLP-1 agonist interactions trigger euglycemic DKA and explore management strategies.
Today

A new study reveals that pregnant women with gestational diabetes show altered neural responses to high-fat visual food cues compared to healthy controls. Using visual evoked potentials, researchers found that these early neurophysiological responses correlate with HbA1c levels and metabolic health.
Today

A multi-state Indian study by KMCRI reveals alarming cardiovascular risk markers among healthy adolescents and young adults, including hyperhomocysteinemia and early blood vessel damage.
Today

A 69-year-old male presented with a painless thigh mass, initially suspected as a primary soft tissue tumor. Post-surgical pathology confirmed squamous cell carcinoma. Subsequent FDG PET/CT and EBUS biopsy identified primary lung cancer, proving skeletal muscle metastasis can be the first sign of occult malignancy.
Today

Per-protocol analysis of the PRAGUE-25 trial demonstrates that catheter ablation significantly reduces atrial fibrillation burden, hospitalizations, and emergency visits compared to lifestyle modification plus antiarrhythmic drugs in obese patients.
Today